A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
Status:
Active, not recruiting
Trial end date:
2022-05-05
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2
dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK)
profile of budigalimab. This study will also evaluate the safety and tolerability of
budigalimab in combination with Rovalpituzumab Tesirine and budigalimab in combination with
venetoclax. The study will consist of 3 parts: budigalimab monotherapy dose escalation and
expansion, budigalimab in combination with Rovalpituzumab Tesirine and budigalimab in
combination with venetoclax.